Diagnostic News and Research

RSS

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Official guidelines for diagnosis, treatment and management of food allergies released

A collaborative, government-led effort to guide and standardize diagnosis, treatment and management of food allergies has resulted in the release of an official set of recommendations for physicians.

10 Dec 2010

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Elekta K.K., a wholly owned subsidiary of Elekta AB, has entered into a sales and marketing agreement with Toshiba Medical Systems Corporation in Japan.

From Elekta 10 Dec 2010

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.

10 Dec 2010

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and The Regents of the University of California, Los Angeles campus, today announced the execution of an exclusive research agreement that will focus on the identification of biological markers of mucosal healing in patients with Inflammatory Bowel Disease (IBD). The research will be led by Dr. Jonathan Braun, Chair of the Department of Pathology and Laboratory Medicine and a professor of molecular and medical pharmacology, UCLA David Geffen School of Medicine.

10 Dec 2010

New molecular tools show promise for cleansing brain of amyloid plaques

New molecular tools developed at the University of Michigan show promise for "cleansing" the brain of amyloid plaques, implicated in Alzheimer's disease.

10 Dec 2010

Scientists to develop ultra-rapid sexually transmitted infection detection system for clinics

Scientists from the University of Southampton have secured funding to develop an ultra-rapid sexually transmitted infection (STI) detection system for clinics that can detect STIs in under 15 minutes.

9 Dec 2010

Ingenuity Systems and CLC bio collaborate to provide interoperability between software solutions

Today Ingenuity Systems and CLC bio announced that they're collaborating to provide interoperability between their software solutions. The aim of the partnership is to provide researchers with the ability to easily exchange data between CLC bio's enterprise and desktop solutions and Ingenuity's pathway analysis software (IPA®), in order to perform both array and next-generation sequencing data and knowledge analyses.

9 Dec 2010

Cardiac Science adds two ECGs to Burdick line

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today adds two electrocardiographs (ECGs) under its Burdick brand, known for its accuracy, reliability, and ease of use. The ECGs, available only in the U.S., deliver built-in, bi-directional communication so customers can connect to leading EMRs.

9 Dec 2010

USAID, PEPFAR and HHS welcome WHO's endorsement of rapid diagnostic test for TB

The United States welcomes the policy statement and roadmap issued today by the World Health Organization (WHO) charting the rollout of the Xpert MTB/RIF rapid diagnostic test for tuberculosis (TB) and rifampicin resistance, a proxy for multidrug resistant tuberculosis (MDR-TB).

9 Dec 2010

St. Jude Medical announces advanced technologies for streamlined workflow in EP lab

St. Jude Medical, Inc., a global medical device company, today announced several new products that provide physicians and hospitals with the opportunity for improved efficiency and information connectivity in the electrophysiology (EP) lab. The EnSite Connect™ Remote Support feature, EnSite Courier™ Module, EnSite Velocity v2.0™ Software and recently launched EnSite Derexi™ Module are advanced technologies that allow a streamlined workflow within the EP lab.

9 Dec 2010

Home health care technology could help patients improve their health, overall well-being: Study

Home health care technology may provide one important solution to global concerns about how to sustain health care systems threatened by rising costs and manpower shortages, but such a change faces multiple obstacles to adoption, according to a new RAND Corporation study.

9 Dec 2010

Personalized medicine advocates push for better reimbursement system

The U.S. reimbursement for diagnostic tests is outdated and inhibits the development of more personalized tests for patients, according to a report released Tuesday by the Personalized Medicine Coalition.

9 Dec 2010

AltheaDx partners with Compendia Bioscience to launch Breast Cancer Segregation Panel Assay

AltheaDx, Inc. today announced the formation of a strategic partnership with Compendia Bioscience to combine their respective core capabilities in assay development, validation and bioinformatics. The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials.

9 Dec 2010

WHO endorses rapid TB test

"The World Health Organization endorsed a new, rapid test for tuberculosis Wednesday that cuts the diagnosis time for patients from months to hours," CNN reports (Gray, 12/8).

8 Dec 2010

Myriad to acquire technology for diagnosis, prognosis of malignant melanoma

Myriad Genetics, Inc. today announced that it has signed an agreement to acquire proprietary technology for the diagnosis and prognosis of malignant melanoma using highly validated genetic markers from Melanoma Diagnostics, Inc. of Altadena, California. Under the agreement, Myriad has the right to commercialize all tests derived from the technology on a worldwide basis in exchange for upfront fees and contingent payments based upon the commercial success of the products.

8 Dec 2010

ChipDX validates genetic signature for early-stage colon cancer

ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.

8 Dec 2010

Children's Hospitals and Clinics of Minnesota installs Toshiba's Infinix CC-i system and MAQUET OR table

To advance its ability to provide patients with the highest quality of care and increase the collaboration between pediatric surgical and interventional doctors, Children's Hospitals and Clinics of Minnesota recently installed Toshiba America Medical System's InfinixTM CC-i cardiac imaging system and the MAQUET OR table to form its new hybrid operating room (OR) suite.

8 Dec 2010

New NIH guidelines support broader use of blood tests to diagnose food allergy

New guidelines on diagnosis and management of food allergy issued by the National Institute of Allergy and Infectious Diseases a part of NIH, supports a broader use of blood test to improve current clinical practice. Phadia's ImmunoCAP is recognized for its superior predictive values compared to other systems. It provides precise, quantitative and standardized results and help doctors make an accurate diagnosis.

8 Dec 2010

WHO endorses new rapid fully automated nucleic acid amplification test for TB

Today, WHO endorsed a new and novel rapid test for tuberculosis (TB), especially relevant in countries most affected by the disease. The test could revolutionize TB care and control by providing an accurate diagnosis for many patients in about 100 minutes, compared to current tests that can take up to three months to have results.

8 Dec 2010

Diagnostic News and Research

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Official guidelines for diagnosis, treatment and management of food allergies released

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

New molecular tools show promise for cleansing brain of amyloid plaques

Scientists to develop ultra-rapid sexually transmitted infection detection system for clinics

Ingenuity Systems and CLC bio collaborate to provide interoperability between software solutions

Cardiac Science adds two ECGs to Burdick line

USAID, PEPFAR and HHS welcome WHO's endorsement of rapid diagnostic test for TB

St. Jude Medical announces advanced technologies for streamlined workflow in EP lab

Home health care technology could help patients improve their health, overall well-being: Study

Personalized medicine advocates push for better reimbursement system

AltheaDx partners with Compendia Bioscience to launch Breast Cancer Segregation Panel Assay

WHO endorses rapid TB test

Myriad to acquire technology for diagnosis, prognosis of malignant melanoma

ChipDX validates genetic signature for early-stage colon cancer

Children's Hospitals and Clinics of Minnesota installs Toshiba's Infinix CC-i system and MAQUET OR table

New NIH guidelines support broader use of blood tests to diagnose food allergy

WHO endorses new rapid fully automated nucleic acid amplification test for TB

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News